Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies

Lupus

Volumn 23, Issue 12, 2014, Pages 1324-1326

  Romay Penabad, Z ^a   Carrera Marin, A L ^a   Willis, R ^a   Weston Davies, W ^b   Machin, S ^c   Cohen, H ^c   Brasier, A ^a   Gonzalez, E B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Volution Immuno Pharmaceuticals Limited SA   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

aPL mediated thrombogenesis; Complement inhibition; coversin

Indexed keywords

CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C5 INHIBITOR; COVERSIN; PHOSPHOLIPID ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BETA2 GLYCOPROTEIN 1; COMPLEMENT COMPONENT C5; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; CONFERENCE PAPER; CONTROLLED STUDY; EXPERIMENTAL THROMBOSIS; HUMAN; MOUSE; NONHUMAN; OPTICAL DENSITY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; IMMUNOLOGY; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; COMPLEMENT C5; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; THROMBOPLASTIN; THROMBOSIS;

EID: 84908664176     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314546022     Document Type: Conference Paper

References (10)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4: 295-306
2. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005 ; 52: 2120-2124
3. Carrera-Marín A, Romay-Penabad Z, Papalardo E, et al. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus. 2012 ; 21: 1497-1505
4. Pierangeli SS, Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: Are we there yet?. Lupus. 2010 ; 19: 475-485
5. Nunn MA, Sharma A, Paesen GC, et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol. 2005 ; 174: 2084-2091
6. Soltys J, Kusner LL, Young A, et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol. 2009 ; 65: 67-75
7. Huber-Lang M, Barratt-Due A, Pischke SE, et al. Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice. J Immunol. 2014 ; 192: 5324-5331
8. Westwood JP, Weston-Davies WH, Hillmen P, et al. Coversin, a small protein complement inhibitor, is a potential novel anti-thrombotic agent. Abstract 5. Abstracts of the 54th Annual Scientific Meeting of the British Society for Haematology, 28-30 April 2014, Birmingham, UK. Br J Haematol. 2014 ; 165: 3-3
9. Pierangeli SS, Harris EN. A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc. 2008 ; 3: 840-848
10. Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation. 1996 ; 94: 1746-1751